CoChat

Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy

Open access
Tang, Xiang-Jun, Sun, Xu-Yong, Huang, Kuan-Ming, Zhang, Li, Yang, Zhuo-Shun, Zou, Dan-Dan, Wang, Bin, Warnock, Garth L., Dai, Long-Jun, Luo, Jie · 2015 · Oncotarget
Cited by 153

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

// Xiang-Jun Tang 1,* , Xu-Yong Sun 2,* , Kuan-Ming Huang 1,* , Li Zhang 1 , Zhuo-Shun Yang 1 , Dan-Dan Zou 1 , Bin Wang 1,3 , Garth L. Warnock 4 , Long-Jun Dai 1,4 and Jie Luo 1 1 Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China 2 Guangxi Key Laboratory for Transplantation Medicine, Institute of Transplant Medicine, 303 Hospital of People’s Liberation Army, Nanning, China 3 The Biomedical Research Center, University of British Columbia, Vancouver, Canada 4 Department of Surgery, University of British Columbia, Vancouver, Canada * These authors have contributed equally to this work Correspondence to: Long-Jun Dai, email: // Jie Luo, email: // Keywords : immunotherapy, chimeric antigen receptor (CAR), exosomes, cancer therapy, extracellular vesicles Received : August 12, 2015 Accepted : October 06, 2015 Published : October 19, 2015 Abstract Chimeric antigen receptor (CAR)-based T-cell adoptive immunotherapy is a distinctively promising therapy for cancer. The engineering of CARs into T cells provides T cells with tumor-targeting capabilities and intensifies their cytotoxic activity through stimulated cell expansion and enhanced cytokine production. As a novel and potent therapeutic modality, there exists some uncontrollable processes which are the potential sources of adverse events. As an extension of this impactful modality, CAR-T cell-derived exosomes may substitute CAR-T cells to act as ultimate attackers, thereby overcoming some limitations. Exosomes retain most characteristics of parent cells and play an essential role in intercellular communications via transmitting their cargo to recipient cells. The application of CAR-T cell-derived exosomes will make this cell-based therapy more clinically controllable as it also provides a cell-free platform to diversify anticancer mediators, which responds effectively to the complexity and volatility of cancer. It is believed that the appropriate application of both cellular and exosomal platforms will make this effective treatment more practicable.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.6175

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 153

Metadata

Authors
Tang, X.-J., Sun, X.-Y., Huang, K.-M., Zhang, L., Yang, Z.-S., Zou, D.-D., Wang, B., Warnock, G. L., Dai, L.-J., & Luo, J.
Venue
Oncotarget
Published
2015-10-19
Volume
6
Issue
42
Pages
44179-44190
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2179030446
Cited by
153
References
23
FWCI
2.44
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.